FDA advisers back BPC-157 compounding, 8–6
On July 23, 2026 FDA advisers voted 8–6 to recommend BPC-157, TB-500 and KPV for the 503A bulks list. The vote is non-binding; compounding isn't legal yet.
Key takeaways
- July 23, 2026: the Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend BPC-157, KPV and TB-500 for the 503A bulks list.
- MOTS-c passed 7–5 (2 abstentions); Semax and Epitalon passed on July 24; emideltide was rejected 7–6.
- FDA staff had recommended against all seven substances.
- Nothing is legal to compound until FDA accepts the advice and completes notice-and-comment rulemaking.
On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides that are widely sold online as “research chemicals” and asked whether each should be added to the 503A bulks list — the list of bulk substances that state-licensed compounding pharmacies may use without an FDA-approved drug behind them.
The votes
| Substance | Vote | Date |
|---|---|---|
| BPC-157 | 8–6, 1 abstention (recommend) | July 23 |
| KPV | 8–6, 1 abstention (recommend) | July 23 |
| TB-500 | 8–6, 1 abstention (recommend) | July 23 |
| MOTS-c | 7–5, 2 abstentions (recommend) | July 23 |
| Semax | Recommend (narrow) | July 24 |
| Epitalon | Recommend (narrow) | July 24 |
| Emideltide (DSIP) | 7–6, 1 abstention (reject) | July 24 |
The outcome was unusual because FDA’s own scientists had recommended against adding any of the seven. Their briefing materials found the human data — including five BPC-157 trials — too short and too small to establish safety or effectiveness for the proposed uses.
What happens next
Advisory votes are not binding. Before any compounding pharmacy could legally use BPC-157, the FDA would need to accept the recommendation and then complete notice-and-comment rulemaking: a proposed rule, a public comment period and a final rule. No timeline has been announced.
Until then, BPC-157 remains unapproved, and products sold online as “research use only” remain outside the drug-quality system.
Why it matters for buyers and clinics
Clinics in our directory already list BPC-157 and TB-500 among their offerings. The vote does not change the legal status of those products today. If you are reading a vendor’s certificate of analysis, the same checks apply as before — see our guide to reading a peptide COA.
For the underlying science, see our profiles of BPC-157, TB-500 and MOTS-c, and the side-by-side BPC-157 vs TB-500.
What the evidence does not show
- That any of these peptides is safe or effective — FDA reviewers called the BPC-157 trials short and underpowered.
- A timeline for FDA's decision.
Frequently asked questions
Did the FDA approve BPC-157?
No. An advisory committee recommended adding BPC-157 to the list of substances 503A pharmacies may compound. That is not a drug approval, and the FDA has not yet acted on the advice.
Which peptides did the committee recommend in July 2026?
BPC-157, KPV and TB-500 (8–6), MOTS-c (7–5), and Semax and Epitalon on July 24. Emideltide was rejected.
Can pharmacies compound BPC-157 now?
Not legally. The FDA must accept the recommendation and finish rulemaking — a proposed rule, public comment and a final rule — first.
Sources
Find a clinic
Our clinic directory lists only clinics whose address and services we confirmed on their own websites, with the date we checked.